Slide 1: Pacific Edge Limited Business Overview
Pacific Edge Limited Business Overview March 2015 First NZ Capital
Slide 2: Gaining traction in key customers of scale in the US
Pacific Edge | Gaining traction in key customers of scale in the US Pacific Edge Regulatory approvals in place for the world’s largest healthcare market specialises in the discovery and • CLIA1 certification received for both the US and NZ laboratory commercialisation of • CAP2 accreditation receive
Slide 3: Commercialisation infrastructure now in place for Australasia, US and SE Asia
Pacific Edge | Commercialisation infrastructure now in place for Australasia, US and SE Asia Published Cxbladder clinical paper in the Journal of Urology Cxbladder Detect launched commercially PEB lists on NZSX, through Produced a pre-commercial Opened US laboratory User Program Cxbladder Triage rai
Slide 4: Target Market: Bladder cancer
Bladder cancer | Currently the highest total medical cost per patient of all cancers Bladder cancer has • Worldwide, bladder cancer is the sixth most prevalent form of cancer (8% of male cancers and 2% of female)1 high prevalence, is with a high recurrence rate extremely costly to treat, and current
Slide 5: Cxbladder: A new class of bladder cancer detection tests
Cxbladder | A new class of bladder cancer detection tests Our suite of products Cxbladder product suite enables us to provide a ‘one-stop shop’ for urologists Cxbladder Detect Cxbladder Triage Cxbladder Monitor Cxbladder Predict In-market In-market Expected launch 2015 Expected launch 2016 Specific
Slide 6: Cxbladder is Highly Accurate
Cxbladder is Highly Accurate | Detects 100% of tumours of concern to Urologists Pacific Edge Cxbladder Alere NMP22 Alere NPM22 ELISA Cytology Detect BladderChek Stage Sensitivity Tis 100% 0% 0% 100% Ta 77% 39% 32% 29% T1 100% 43% 71% 50% T2 100% 13% 57% 100% Overall Sensitivity 82% 35% 45% 46% Speci
Slide 7: Cxbladder Detect vs. Triage
Cxbladder Detect vs. Triage | Different strengths provide complimentary results Cxbladder Triage Cxbladder Detect Non-invasive, requires single urine sample sent to our lab ✔ ✔ Test result output Quantitative inputs, binary output Quantitative inputs quantitative output score Early evaluation of hem
Slide 8: Lab throughput data is a measure of adoption
Cxbladder | Lab throughput data is a measure of adoption Lab throughput is the Lab throughput showing significant improvements strongest tangible measure of adoption for Pacific Edge Throughput has continued to improve substantially throughout the first full year of trading in the US Q4 FY15 has als
Slide 9: Kaiser Permanente User Program example
Kaiser Permanente User Program example | Saving a large payer significant cost Pacific Edge recently signed a User Program Kaiser Permanente is a fully Integrated Healthcare Provider (IHCP), from the time the patient enters the healthcare agreement with Kaiser system to their post treatment manageme
Slide 10: Scientific papers
Scientific papers | Two published journal articles with another two pending / under review Our technology is Published clinical and science papers: underwritten by a strong intellectual • Holyoake et al (2008). Development of a Multiplex RNA Urine Test for the Detection and Stratification of propert
Slide 11: Markets: Cxbladder products in market in Australasia and the US
Markets | Cxbladder products are currently in market in Australasia and the US Pacific Edge started the evaluation of the South East Asian market during 2014 and are on track to initiate a commercial presence by April 2015 South East Asia represents a novel market opportunity based around medical to
Slide 12: Experienced Board and senior executive team
Pacific Edge | Experienced Board and senior executive team Key senior executive team members David Darling, CEO Jackie Walker, CEO Parry Guilford, CSO Jimmy Suttie, COO Pacific Edge and Group Pacific Edge Diagnostics USA Pacific Edge Pacific Edge Dave has over 30 years’ business Jackie brings to the
Slide 13: The opportunity: Objectives for 2015 / 2016
The opportunity | Objectives for 2015 / 2016 Launch into SE Asia via Singapore Appoint supply chain logistics provider Employ on the ground sales Initiate four key user programmes with leading hospitals and clinics Follow up in Bangkok and Taipei targeting medical tourists Escalation of growth in th
Slide 14: David Darling, CEO, Pacific Edge Limited
David Darling CEO, Pacific Edge Limited dave.darling@pelnz.com www.pacificedge.co.nz www.cxbladder.com www.pacificedgedx.com www.bladdercancer.me
Slide 15: Safe Harbour Statement
Safe Harbour Statement Statements in this presentation about Pacific Edge’s expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. These statements are often, but not always, made through the use of words or